Pluristyx, a biotechnology company, has executed two commercial clinical use licensing agreements. These agreements provide access to Pluristyx’s clinical-grade iPSC lines and gene engineering platform technologies. The goal is to develop next-generation cell therapies.
Advancing Neurological and Regenerative Therapies
One agreement is with a company developing a treatment for a neurological disease. This partnership will use Pluristyx’s iPSC lines to create a therapy to slow or reverse a neurodegenerative disease.
The second agreement is with a company in regenerative medicine. This agreement licenses Pluristyx’s engineered cell lines, including the iACT™ immune cloaking system and FailSafe® safety-switch technology. This will help develop an allogeneic “off-the-shelf” cell therapy.
| Agreement Focus | Technology Used | Therapeutic Goal |
| Neurological Disease | Clinical-grade iPSC lines | Slow or reverse neurodegenerative disease |
| Regenerative Medicine | iACT™ immune cloaking, FailSafe® safety-switch | Develop allogeneic “off-the-shelf” cell therapy |
Pluristyx’s iPSC Platform
Pluristyx’s platform offers a direct path from research to clinical application. It provides high-quality, regulatory-compliant starting materials and advanced gene-engineered solutions. This helps therapeutic developers to streamline their work.
Dr. Benjamin Fryer, CEO of Pluristyx, stated that these agreements validate the platform’s power and versatility. He emphasized the company’s mission to accelerate the delivery of life-changing therapies.
About Pluristyx
Pluristyx provides advanced iPSC-based solutions for the cell and gene therapy industry. The company’s platform is designed to accelerate therapeutic development with speed, safety, and scalability. Pluristyx supports the entire development process, from concept to manufacturing.
These new agreements mark a significant step for Pluristyx. They highlight the company’s role in advancing cell therapies for neurological and regenerative medicine.
For more info visit: www.pluristyx.com
